We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment.
All Keywords
【저자키워드】 COVID-19, SARS CoV-2, serology, neutralization, enzyme immunoassay, PRNT, microneutralization, 【초록키워드】 SARS-CoV-2, coronavirus, antibody, virus, anti-SARS-CoV-2, Laboratory, Neutralization assay, sera, neutralizing capacity, acute respiratory syndrome, wild-type, offer, characterized, 【제목키워드】 SARS-CoV-2, anti-SARS-CoV-2 antibody, performance, WT SARS-CoV-2, virus-neutralizing,
【저자키워드】 COVID-19, SARS CoV-2, serology, neutralization, enzyme immunoassay, PRNT, microneutralization, 【초록키워드】 SARS-CoV-2, coronavirus, antibody, virus, anti-SARS-CoV-2, Laboratory, Neutralization assay, sera, neutralizing capacity, acute respiratory syndrome, wild-type, offer, characterized, 【제목키워드】 SARS-CoV-2, anti-SARS-CoV-2 antibody, performance, WT SARS-CoV-2, virus-neutralizing,